- Biotechnology and Orthopedics Report - 84 pages of exclusive interviews, featuring:
- Roundtable Forum: Kevin DeGeeter, Oppenheimer & Co. Inc.; George Huang, Stansberry & Associates; Shivpreet Singh Kapoor, Ferris, Baker Watts Incorporated
- Small & Mid-Cap Biotech Companies - Dr. Simos Simeonidis, Broadpoint Capital
- Direct-Acting AntiVirals & Hepatitis C - Liisa Bayko, JMP Securities LLC
- Orthopedics: Spinal Segment - Ben Andrew, William Blair & Company, LLC
- Minimally Invasive Spine Surgical Outlook - John Putnam, Dawson James Securities, Inc.
- CEO Interviews - Amarillo Biosciences, Inc., Cleveland BioLabs, Inc., Encorium Group, Inc., Hemispherx Biopharma, Inc., Living Cell Technologies Limited, MannKind Corporation, Maxygen, Inc., Nabi Biopharmaceuticals, Opexa Therapeutics, Inc., Provectus Pharmaceuticals, Inc., SciClone Pharmaceuticals, Inc., Stellar Pharmaceuticals Inc., Vitro Diagnostics, Inc.
- Topics covered include: FDA approval process - Failures in oncology trials - Safety concerns - Public and private funding - PIPES and structured financing - Big Pharma partnerships - Development stage companies - Late-stage product companies - Technology platform companies - Outsourcing trends & CRO - Outlook for oncology companies - Urology companies and latest developments - Stock recommendations - Stocks to worry about
- Companies mentioned include: Genentech (DNA); ZymoGenetics ZGEN); AEterna Zentaris (AEZS); Sequenom (SQNM); ImmunoGen (IMGN); Genzyme (GENZ); Alnylam Pharmaceuticals (ALNY); Isis Pharmaceuticals (ISIS); Arena Pharmaceuticals (ARNA); Vertex Pharmaceuticals (VRTX); Progenics Pharmaceuticals (PGNX); Myriad Genetics (MYGN); Synta (SNTA)
|
0 items
